Eptinezumab is a monoclonal antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity, preventing the activation of the CGRP receptors. CGRP is a signaling molecule implicated in ​the pathophysiology of migraine.

Bexicaserin is an investigational, oral, centrally acting, highly selective superagonist of the 5-HT₂꜀ receptor. Bexicaserin may reduce the frequency of seizures associated with DEEs by augmenting the activity of 5-HT₂꜀-expressing inhibitory interneurons within epileptogenic brain regions, while minimizing adverse effects associated with activation of other receptor subtypes. 

Amlenetug is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular α-synuclein and thereby intended to prevent uptake and inhibit seeding of aggregation. 

Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology.

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

Lu AG13909 is a humanized IgG1 mAb that specifically binds to ACTH with high affinity and inhibits ACTH-induced melanocortin signalling. The compound is being developed by Lundbeck as a treatment for conditions characterized by chronically elevated ACTH.

Lu AG13909 is a humanized IgG1 mAb that specifically binds to ACTH with high affinity and inhibits ACTH-induced melanocortin signalling. The compound is being developed by Lundbeck as a treatment for conditions characterized by chronically elevated ACTH.

Lu AG22515 is a novel CD40L blocker that inhibits an essential co-stimulatory signal involved in the activation of adaptive immune responses, as well as local pro-inflammatory response. Blocking CD40L holds strong promise in the treatment of a wide range of autoimmune-related neurological diseases​.

Monoacylglycerol lipase (MAGL) is the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG on CB1 and CB2 receptors may restore altered neuronal transmission and neuroinflammation and thereby it may produce beneficial effects across a range of symptoms and related indications including PTSD, Fibromyalgia, spasticity in patients with multiple sclerosis and focal epilepsy.